A More Efficient, Innovative and Greener 11.11 Runs Wholly on Alibaba Cloud
14.11.2022 05:42:00 EET | Business Wire | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, has once again excelled in its mission of supporting the group’s 11.11 Global Shopping Festival, thanks to its high-performance computing and innovative technology. Drawing on self-developed infrastructure upgrades, the group saw an 8% year-on-year saving in computing cost per resource unit from April 1 to November 11.
“The breadth and depth of cloud technology deployment during this year’s 11.11 has once again showcased Alibaba’s best cloud and technology practice; be it through fundamental architecture like self-proprietary technology powering high-performance computing and database products, or consumer-facing XR (extended reality) and livestreaming technologies. We intend to continue applying these proven capabilities to even better serve our customers and help them to be more efficient, innovative and greener in their own digital transformation journeys,” said Li Cheng, Chief Technology Officer (CTO) of Alibaba Group.
Doing more with less through cloud-native and serverless innovations
This year’s 11.11 was powered by Alibaba Cloud’s dedicated processing unit for the Apsara Cloud operating system. The upgraded infrastructure system, significantly improved efficiency of computing, storage and network in data centers supporting the event, while also reducing network latency. For example, with this new upgrade supported by cloud-native technology, ordering, pre-sale balance payment and refunding could be launched simultaneously with an enhanced scalability and lower latency.
During this year’s 11.11, the front page of Taobao, one of Alibaba’s e-commerce platforms, was upgraded by the latest serverless technology, allowing for automatic scaling with extreme elasticity based on actual workloads.
Alibaba Cloud’s cloud-native database products also significantly expanded the capacity of consumers’ shopping carts by more than a double, from 120 items to 300. The ApsaraDB for Redis Enhanced Edition (Tair), a cloud-based in-memory database service for enterprises, supports new functions such as product grouping and sorting, enabling consumers to organize their shopping cart according to their own preferences. They could also make use of the ‘select’ function to enjoy cross-merchant discounts, to pre-order goods and use vouchers for a more rewarding shopping experience.
Innovative technology delivers more immersive consumer experience
A more immersive shopping experience was created this year thanks to Alibaba’s proprietary technology in supporting extended reality. Alibaba’s technology in 3D modeling leverages a neural radiance field (NeRF), a neural network technology for generating novel views of complex 3D scenes. During this year’s 11.11, it assisted luxurious retail and furniture brands, like Burberry, Estee Lauder and SK-II, to build virtual stores on the e-commerce platform Tmall.
Through self-developed 3D renderings that realistically represent natural light, flames and natural flowing water, an outdoor nature scene was built for sportswear brands including Descente (Japan), to showcase its latest products in a vibrant and invigorating environment. Consumers can also view the products in three dimensions, enabling them to inspect details up close, or try on their chosen watches and accessories virtually thanks to AR technologies. Consumers are also free to arrange different items of furniture indoors, or tents for outdoor camping.
Another new expressive interaction came from an XR-powered marketplace on Tmall and Taobao. Using the automatic 3D space creation technology from Alibaba’s research institute DAMO Academy, a virtual shopping street was built, featuring over 700 products from 70 brands including 30 internationally-recognized franchises, such as Sanrio’s iconic Hello Kitty, and Hollywood’s franchise Minions. Shoppers can choose their own avatars, check out the products and place them in their virtual shopping carts.
During this year’s 12-day festival from October 31 to November 11, nearly 2 million packages were delivered by Xiaomanlv vehicles, Alibaba’s last-mile logistics vehicle. This is double the package delivery volume from the same period last year. The logistics robot was deployed in over 400 campuses across China, which has greatly reduced the time of queuing for package deliveries during peak hours.
A greener 11.11 powered by clean energy
In addition to its cloud computing solutions helping to reduce energy consumption, Alibaba Cloud’s five hyper-scale data centers across China also doubled the amount of clean energy used to support this year’s 11.11 compared to last year. More than 32 million kilowatt-hours of electricity used by Alibaba Cloud to support 11.11 this year came from renewable energy, up by 30% on a daily basis average compared to last year. Additionally, Alibaba Cloud's Heyuan data center, the cloud company’s largest hyper-scale data center in South China, now runs entirely on clean energy. Alibaba Cloud’s self-developed immersion cooling technology has reduced the energy consumption of the data centers, with power usage effectiveness (PUE) reaching as low as 1.09 - a world-leading level.
Alibaba Cloud has also worked with Tmall to leverage the carbon management platform, Energy Expert. It provided online carbon footprint modeling, calculations and certifications for more than 40 brands in various sectors, including paper & pulp, food and personal care, to help them categorize low-carbon products, identify carbon emission resources and conduct informed sustainability practices to reduce carbon emissions.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, management and application services, big data analytics, a machine learning platform and IoT services. Alibaba maintained its position as the third leading public cloud IaaS service provider globally since 2018, according to IDC. Alibaba is the world’s third leading and Asia Pacific’s leading IaaS provider by revenue in U.S. dollars since 2018, according to Gartner.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005119/en/
Contact information
Xiaoyi Shao
Alibaba Group
+86 18658170996
shaoxiaoyi.sxy@alibaba-inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
